Social Capital Suvretta Holdings Corp I

Social Capital Suvretta Holdings Corp I — SPAC Merger (April 2022)

70 slides from Social Capital Suvretta Holdings Corp I's SPAC merger presentation, Apr 28, 2022

  1. Slide 1: Welcome

    Welcome. 2

  2. Slide 2: About this presentation

    About this presentation This investor presentation ( Presentation ) contains proprietary and confidential information of Social Capital Suvretta Holdings Corp. I (“SCS”) and Akili Interactive Labs, Inc. (“Akili” or the “Company”), and the entire content should be considered “Confidential Information”

  3. Slide 3: About this presentation: Use of Projections

    About this presentation USE OF PROJECTIONS This Presentation contains certain financial forecasts of the Company. Neither SCS’ nor the Company’s independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusio

  4. Slide 4: Establishing a new era of cognitive medicine through game-changing technologies

    Establishing a new era of cognitive medicine through game-changing technologies 5

  5. Slide 5: Akili milestones timeline

    Akili study grabs attention with digital therapeutic for adults with MDD and new hire Akili and Pfizer successfully gamify Alzheimer's In a landmark decision, FDA greenlights a video game for kids with ADHD 2013 2016 2018 2020 2020 2022 1st PIVOTAL TRIAL PURPOSE-BUILT DTX 1st PATENT 1st FDA CLEARANCE

  6. Slide 6: Management team

    EDDIE MARTUCCI, PHD Chief Executive Officer, Co-Founder Former: PureTech Health ANIL JINA, MD SANTOSH SHANBHAG Chief Medical Officer Chief Financial Officer Former: Pfizer, Sanofi, Shire, PPD Former: Vertex Pharmaceuticals JACKIE STUDER JON DAVID Chief Legal Officer & General Counsel Chief Product Officer

  7. Slide 7: Agenda

    Clinically Validated Science Platform in Action: Product Approach & Overview Pipeline: Clinical Research and Strategy Break Agenda Fireside Chat: Payer Perspective ADHD Market & EndeavorRx Commercial Launch Plan Revenue Opportunity & Financial Overview Closing Remarks (+ Bonus Content) Q&A 8

  8. Slide 8: Brain function is the next frontier

    Brain function is the next frontier 9

  9. Slide 9: Recognition of cognitive issues is at an all time high

    Recognition of cognitive issues is at an all time high MULTIPLE ADHD 64% SCLEROSIS experience adverse 2 effects from medication up to86% up to60% 1 of children have attention deficits of adults have cognitive impairments that may result in a decrease in 3 independence and quality of life DEPRESSION D

  10. Slide 10: Cognitive impairments exist across many medical conditions

    Cognitive impairments exist across many medical conditions MULTIPLE PARKINSON'S ADHD SCLEROSIS ALZHEIMER’S BIPOLAR DISORDER TRAUMATIC AUTISM ANXIETY BRAIN VASCULAR DISEASE INJUR Y LUPUS MCI PTSD DIABETES AGING DEPRESSION DEMENTIA SCHIZOPHRENIA CHEMO-FOG SENSORY PROCESSING DISORDER CHRONIC PAIN HUNTI

  11. Slide 11: The need is significant

    TEEN VOGUE “Social media use has been linked to increased anxiety, depression, sleep disruption, anti-social behavior, and even found to be predictive of future suicide risk for teen girls.” LOS ANGELES TIMES - OP-ED “Social media has played a role in shortening people's attention span by a significa

  12. Slide 12: Akili has set the standard for clinical validation in digital medicine

    Akili has set the standard for clinical validation in digital medicine 16 Peer-reviewed Cognitive dysfunction in… publications ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ALZHEIMER’S DISEASE (AD) AUTISM SPECTRUM DISORDER (ASD) ™ DEPRESSION (MDD) SSME 20 9 ™ Selective Stimulus SSME Disease Clinic

  13. Slide 13: Clinically Validated Science

    Clinically Validated Science DR. ANIL JINA, CHIEF MEDICAL OFFICER 14 14

  14. Slide 14: SSME is designed to target frontoparietal attention control networks

    SSME™ is designed to target frontoparietal attention control networks Attention Control: Capacity to apply necessary attention at appropriate time and place, while monitoring environment for new sources of information, to enable optimal processing of task-relevant information. A set of neural proces

  15. Slide 15: Founding Science Behind Akili and SSME

    ™ Founding Science Behind Akili and SSME Basic scientific mechanisms underlying SSME were tested in a series of controlled studies and published in Nature in 2013 They utilized a specifically designed video game with simultaneous cognitive tasks (perceptual discrimination in the setting of continuous

  16. Slide 16: Founding Science Behind Akili and SSME

    ™ Founding Science Behind Akili and SSME This specifically designed technology showed its potential to: • Sensitively assess cognitive function (linear age-related cognitive decline) • Positively impact cognitive function after 4 weeks of treatment (improved cognitive measures in older adults compare

  17. Slide 17: Effects of SSME on neural signatures of prefrontal attention control

    LETTER RESEARCH ™ Effects of SSME on neural signatures of prefrontal attention control 13 (vigilance; test of variables of attention (TOVA) ) only for the MTT a group (Fig. 3c; see Supplementary Table 2). In addition, there were Midline frontal theta ™ ™ Control Pre-SSME Post-SSME severalstatistical

  18. Slide 18: Platform in Action: Product Approach & Overview

    Platform in Action: Product Approach & Overview CARL GOTTLIEB , SVP ENGINEERING JON DAVID , CHIEF PRODUCT OFFICER 19 19

  19. Slide 19: Game-changing technology approach to target brain function

    Game-changing technology approach to target brain function Proprietary sensory and motor stimuli designed to target specific neural physiology Delivered through closed-loop, adaptive and personalized algorithms Validated through rigorous clinical trials and mechanistic studies Encoded into engaging i

  20. Slide 20: EndeavorRx game mechanics overview

    ® EndeavorRx game mechanics overview ™ SSME NAVIGATION FOCUS Steer over gates and/or avoid obstacles INTERFERENCE PROCESSING TA R G E T I N G Tap for targets and ignore non-targets MULTITASKING MULTITASKING Simultaneous navigation and targeting 21

  21. Slide 21: Closed-loop system

    Closed-loop system SSME” — AKILI

  22. Slide 22: EndeavorRx game mechanics overview

    ® EndeavorRx game mechanics overview 23

  23. Slide 23: ERx Demo Video

    ERx Demo Video (JD) 24 24

  24. Slide 24: Companion App for Caregivers

    Companion App for Caregivers Tracking Progress Provides caregivers with a daily snapshot of their child’s in-game progress. Compliance Caregivers can follow along with their child’s effort and level completion. Support ® experts if they need help. Caregivers can connect with Akili Assist 25 25 25

  25. Slide 25: Core development capability: population-tailored expansion

    Core development capability: population-tailored expansion/differentiation Core cognitive engine remains intact, while creating completely unique games tailored for each audience and personalized for each individual All games include the key ™ SSME components yet are completely unique games designed

  26. Slide 26: Pipeline: Clinical Research and Strategy

    Double-click to edit Double-click to edit Pipeline: Clinical Research and Strategy DR. ANIL JINA, CHIEF MEDICAL OFFICER 27 27

  27. Slide 27: Current Akili pipeline

    Current Akili pipeline: initial populations demonstrating potential breadth of technology RESEARCH POC PIVOTAL COMMERCIAL Pediatric ADHD 8-12 y/o (US) Pediatric ADHD (EU) Pediatric ADHD 6-17 y/o (Japan) SSME™ Pediatric ADHD 13-17 y/o (US) Adult ADHD 18+ y/o (US) ® Early childhood ADHD 3-8 y/o (US) A

  28. Slide 28: ADHD clinical studies

    ADHD clinical studies clinical trials children + 5 conducted with 600 with ADHD 1 2 3 4 5 STARS STARS-Adjunct POC SPD ASD Sensory Processing Autism Spectrum ADHD ADHD ADHD Population Disorder + ADHD Disorder + ADHD AKL-T01 (no meds) AKL-T01 (on meds) AKL-T01 AKL-T01 AKL-T01 Intervention Arms Digital

  29. Slide 29: ADHD clinical studies: endpoints and safety

    ADHD clinical studies STARS STUDY ADJUNCT STUDY PRIMARY ENDPOINT PRIMARY ENDPOINT Significant improvement in ADHD symptom and impairment improvement sustained after 1st treatment, objective attention compared to 1 increased after 2nd treatment, and similar matched control 2 with or without medication

  30. Slide 30: STARS ADHD study: responder rate forest plot

    STARS ADHD study: responder rate forest plot 31 Kollins et al, Lancet Digital Health, 2020 2(4), e168–e178

  31. Slide 31: EndeavorRx responder rates across studies

    ® 1,2 EndeavorRx treatment of - responder rates across studies 2ND MONTH 1ST MONTH TREATMENT TREATMENT MEASUREMENT RESPONSE RATE DESCRIPTION (STARS) (STARS ADJUNCT) (STARS ADJUNCT) Objective Attention % children moving into normative range in at least one 36% - - objective measure of attention (TOVA

  32. Slide 32: ADHD pipeline and partnerships

    ADHD pipeline and partnerships ® ADHD (13-17 years) pivotal trial underway ® 4 week study of EndeavorRx in 165 children aged 13-17 years with inattentive/combined ADHD years underway. Data availability H2 2023 ® ADHD (Adults 18+ years) pivotal trial underway ® 6 week study of EndeavorRx in 300 adult

  33. Slide 33: Autism spectrum disorder (ASD)

    2 US PAT I E N T S Autism spectrum disorder (ASD) 1.3M 410K TOTAL TA R G E T SSME (n=11) Children with ASD are at high risk for impairments in 0.8 2.5 1 Control (n=7) attention function 0.6 2 The presence of ADHD symptoms in children with autism 0.4 spectrum disorder is associated with worse cogniti

  34. Slide 34: Multiple sclerosis (MS)

    US 4 PAT I E N T S Multiple sclerosis (MS) 900K 180K TOTAL TA R G E T Incidence of cognitive dysfunction in MS ranges from 7 SSME (n=20) 1 20-60% Control (n=20) 6 It is predictive of loss of employment, loss of quality of life, 5 1 and affects all aspects of daily life clinically meaningful 4 change

  35. Slide 35: Major depressive disorder (MDD)

    US 4 PAT I E N T S Major depressive disorder (MDD) 19M 2.1M TOTAL TA R G E T 5 SSME (n=37) Cognitive symptoms are present during up to 94% of Control (n=37) 4 1 depressive episodes and up to 44% of periods of remission 3 4.3 2 Serious impact on patients' quality of life and activities of 1 1 daily l

  36. Slide 36: Acute cognitive dysfunction

    US 2 PAT I E N T S Acute cognitive dysfunction 700KTBI 1.3MCOVID1MCHEMO 300KICU 81M TOTAL TA R G E T Cognitive impairments can occur after acute insults to the brain due to trauma, infection, hypoxia, inflammation, medication, toxins, critical illness, cancer etc. SSME (n=28) 0.4 Control (n=28) No Ga

  37. Slide 37: Cognitive monitoring

    Cognitive monitoring Cognition is often only assessed when there is a specific, subjective complaint from patients, family members, or 1 caregivers There is no consistent clinical protocol for how to use 1 cognitive assessment tools Most cognitive assessments have not changed in decades 1 and many ar

  38. Slide 38: Break

    Break 39 39

  39. Slide 39: Break

    Break 40 40

  40. Slide 40: Break

    Break 41 41

  41. Slide 41: Break

    Break 42 42

  42. Slide 42: Break

    Break 43 43

  43. Slide 43: Break

    Break 44 44

  44. Slide 44: Fireside Chat: Payer Perspective

    Fireside Chat: Payer Perspective ROB PEREZ, EXECUTIVE BOARD CHAIR & DIRECTOR OPERATING PARTNER GENERAL ATLANTIC, FORMER CUBIST PRESIDENT & CEO KEN EHLERT, BOARD DIRECTOR & FORMER CHIEF SCIENTIFIC OFFICER, UNITEDHEALTH GROUP 45

  45. Slide 45: ADHD Market & EndeavorRx Commercial Launch Plan

    ADHD Market & EndeavorRx Commercial Launch Plan ASHLEIGH CHUNG VP COMMERCIAL STRATEGY AND OPERATIONS 46 46

  46. Slide 46: Medicine developed, delivered and experienced in a completely new way

    Medicine developed, delivered and experienced in a completely new way 47

  47. Slide 47: EndeavorRx has a large and attractive initial target population

    ® EndeavorRx has a large and attractive initial target population in addressing attention issues 3 ADHD MARKET - US ONLY (patients in millions) 11M Current prescription ADHD treatments in the US address large patient populations 4.7M 8M ADULT 1 $ 3.3M ~ 10Bn ADULT ADHD MARKET 2.8M AGES 13-17 1.9M AG

  48. Slide 48: First of its kind digital treatment delivered through a video game interface

    First of its kind digital treatment delivered through a video game interface; currently being prescribed by physicians and helping pediatric patients with ADHD and their families FDA indication: EndeavorRx® is a digital therapeutic indicated to improve attention function as measured by computer-base

  49. Slide 49: Pediatric ADHD

    1 Pediatric ADHD of children with ADHD spend per ADHD child vs. % have attention deficits neurotypical child 86 5x patients tried/trying/plan to try not currently on or well % % non-pharmacological treatments controlled by medication 55 44 50 1. Willcutt (2012) Neurotherapeutics, 9(3): 490-499; addit

  50. Slide 50: Current treatments and approaches are inadequate

    Current treatments and approaches are inadequate A new category of medicine Physiologically-active DTx Pharmaceuticals Behavioral therapy • Can lead to mixed results • Largely treats • MOA-based efficacy symptoms • Positive safety profile • Can have accessibility and (vs. function) cost issues • FDA c

  51. Slide 51: Commercialization model

    Commercialization model Customer-driven model Prescription-therapeutic, hybrid self-pay reimbursement model. Catalyzed by activated consumers (parents unsatisfied with current treatment options) and efficient HCP education and e-prescribing Frictionless Delivery Option for patient doctor or streamline

  52. Slide 52: EndeavorRx steps to therapy

    ® EndeavorRx steps to therapy VIRTUAL OR IN-PERSON HCP PRESCRIBES VISIT WITH HCP ENDEAVORRX to discuss EndeavorRx as Through PhilRx that will assist with treatment option prior authorization AKILI ASSIST is committed to supporting caregivers along the journey through our Nurse Navigators and other h

  53. Slide 53: Go-to-market plan for EndeavorRx

    ® Go-to-market plan for EndeavorRx Commercial launch 2H 2022, launch indication 8-12 y/o with age expansion studies underway • PDT market development ® • EndeavorRx engagement in most responsive markets • Focus on stimulant naive and patients not well-controlled on current therapy HCP Payer Consumer

  54. Slide 54: Go-to-market plan: Consumer

    ® Go-to-market plan for EndeavorRx Commercial launch 2H 2022, launch indication 8-12 y/o with age expansion studies underway • PDT market development ® • EndeavorRx engagement in most responsive markets • Focus on stimulant naive and patients not well-controlled on current therapy HCP Payer Consumer

  55. Slide 55: Go-to-market plan: HCP

    ® Go-to-market plan for EndeavorRx Commercial launch 2H 2022, launch indication 8-12 y/o with age expansion studies underway • PDT market development ® • EndeavorRx engagement in most responsive markets • Focus on stimulant naive and patients not well-controlled on current therapy HCP Payer Consumer

  56. Slide 56: Go-to-market plan: Payer

    ® Go-to-market plan for EndeavorRx Commercial launch 2H 2022, launch indication 8-12 y/o with age expansion studies underway • PDT market development ® • EndeavorRx engagement in most responsive markets • Focus on stimulant naive and patients not well-controlled on current therapy HCP Payer Consumer

  57. Slide 57: Revenue Opportunity & Financial Overview

    Double-click to edit Double-click to edit Revenue Opportunity & Financial Overview SANTOSH SHANBHAG, CHIEF FINANCIAL OFFICER 58

  58. Slide 58: Increasing TAM through label and indication expansion

    (Total Addressable Market) Increasing TAM through label and indication expansion Total Market 10.8 19.0 81.0 166 2 2.0 1.3 0.9 Population (in millions) Initial target 3.3 15.5 1 population OVER 9.5M PATIENTS (in millions) IN ADHD ALONE 2.1 0.4 0.2 1.4 8.1 ADULT 3.3 13-17 1.9 FDA 8-12 1.8 CLEARED 3-7

  59. Slide 59: Expected ADHD label expansion

    Expected ADHD label expansion 2 INITIAL TARGET POPULATION SIZE (patients in millions) 8.1 TOTAL ADHD MARKET - US ONLY 1.1 POC start: H1 ’22 3-7 YEAR-OLD 4 3.3 Pivotal data: H2 ’23 3 ADULT 1.9 Pivotal data: H2 ’23 13-17 YEAR-OLD 2 FDA CLEARED 1.8 8–12 YEAR-OLD 1 Launch: H2 ‘22 1 TIME 60 1. Timeframes

  60. Slide 60: $500M+ revenue potential in the US in 5-7 years in ADHD alone

    + $500M Revenue potential in the US in 5-7 yrs in ADHD alone $500M+ per yr. US ADHD revenues (estimated in 5-7 yrs) Upside potential: • Additional payor coverage over-time reduces % of $300M $200M self-pay st 1.5 Rx refills per patient after 1 Rx • Reduced gross-to-net discounting • Ability to adapt

  61. Slide 61: EndeavorRx key drivers of the model

    ® EndeavorRx - key drivers of the model METRIC DEFINITION Total prescriptions written by HCP Total Rx Written TRx that that are new prescriptions New Rx DEMAND TRx that that are refill prescriptions Refill Rx # HCPs who wrote an EndeavorRx prescription that quarter Total Prescribers # HCPs who wrote t

  62. Slide 62: EndeavorRx key drivers of the model

    ® EndeavorRx - key drivers of the model PHASE PRE-LAUNCH PRE-LAUNCH PRE-LAUNCH GROWTH METRIC FY 2021 Q1’22 VS.Q1’21 1,713 668 229% Total Rx Written 1,422 503 166% DEMAND New Rx 291 165 1079% Refill Rx 877 437 191% Total Prescribers 832 239 96% ENGAGEMENT New Prescribers 57% 53% (14%) Conversion (Enro

  63. Slide 63: Balance sheet expected to support operations into early 2024

    Balance sheet expected to support business operations into early 2024 in max redemption scenario and 2025 in min redemption scenario ALL NUMBERS IN $ THOUSANDS YEARS ENDED DECEMBER 31 2020 2021 REVENUES: COLLABORATIVE REVENUES 3,927 352 PRODUCT REVENUES 12 186 TOTAL REVENUES 3,939 538 COST OF REVENU

  64. Slide 64: Current Akili pipeline and next milestones

    Current Akili pipeline: initial populations demonstrating potential breadth of technology 1 ESTIMATED NEXT MILESTONE TIMEFRAME Launch Pediatric ADHD 8-12 y/o (US) H2 ‘22 Launch Pediatric ADHD (EU) - - Pediatric ADHD 6-17 y/o (Japan) Initiate Phase III study SSME™ H2 ‘22 Pivotal trial data H2 ‘23 Ped

  65. Slide 65: Closing Remarks

    Double-click to edit Double-click to edit Closing Remarks EDDIE MARTUCCI, CHIEF EXECUTIVE OFFICER 66 66

  66. Slide 66: Leading digital medicine company, premier platform targeting cognitive dysfunction

    Leading digital medicine company, premier platform designed to target cognitive dysfunction across medicine Leading platform using software to treat brain function at scale Product designed to directly target neural physiology and delivered through high-quality entertainment experiences 1 2 First-of

  67. Slide 67: Platform and infrastructure can be leveraged to achieve scale

    Platform and infrastructure can be leveraged to achieve scale, efficiency and speed to market 79 79

  68. Slide 68: 80 80

    80 80

  69. Slide 69: Thank you. Q&A

    Thank you. QA 81

  70. Slide 70: Sources supporting slides

    Sources supporting slides Disease Area Source of Total Population Source for calculations supporting Initial Target Population ADHD 4-7 CDC Survey Estimates, 2014 National Survey on Children's Health (CDC); 2003-2011 ADHD 8-12 Danielson (2018) J Clin Child Adoles Psychol., 47(2): 199-212 Willcutt (2

Social Capital Suvretta Holdings Corp. I — SPAC Merger (April 2022) on 6ix